Literature DB >> 17308858

Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.

Shuang Ye1, Xiao-xiang Chen, Xiao-ye Lu, Mei-fang Wu, Yun Deng, Wen-qun Huang, Qiang Guo, Cheng-de Yang, Yue-ying Gu, Chun-de Bao, Shun-le Chen.   

Abstract

The aim of the study was to investigate the characteristics of adult clinically amyopathic dermatomyositis (CADM) with rapid progressive interstitial lung disease (ILD). Hospitalized patients with dermatomyositis (DM) and polymyositis (PM) between 1998 and 2005 in the Shanghai Renji Hospital were retrospectively studied. One hundred and forty-five patients were classified into CADM, classic DM or PM according to the modified Sontheimer's definition or Bohan-Peter's classification criteria. They were further stratified based on the presence or absence of clinical ILD. The Kaplan-Meier survival analysis and COX regression were performed. The predictive factors for ILD and other clinical properties of CADM-ILD were explored. The presence of clinical ILD was a significant risk factor for the poor outcome of DM/PM (OR = 4.237, CI 95%: 1.239-14.49, p = 0.021). Other risk factors are the presence of rashes and elevated urea nitrogen. Patients with DM/PM complicated by ILD had different clinical courses. Patients with CADM-ILD showed a rapidly progressive pattern with 6-month survival rate of 40.8%. The DM-ILD manifested a progressive pattern with a 5-year survival rate of 54%, while PM-ILD was chronic with 5- and 10-year survival rate of 72.4% and 60.3%, respectively. Better preserved muscle strength, elevated erythrocyte sedimentation rate, and hypoalbuminemia may herald ILD in DM/PM. Patients with CADM-ILD who later died had lower PO(2), higher lactate dehydrogenase, and prominent arthritis/arthralgia compared with those who survived. The presence of antinuclear antibody seems to be protective. Rapid progressive CADM-ILD is refractory to conventional treatment. ILD is a common complication in over 40% of our hospitalized DM/PM cohort and is also a prominent prognostic indicator. CADM is a special phenotype of DM/PM. CADM-ILD, which is usually rapidly progressive and fatal, requires further investigation.

Entities:  

Mesh:

Year:  2007        PMID: 17308858     DOI: 10.1007/s10067-007-0562-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  32 in total

1.  Privatization and its discontents--the evolving Chinese health care system.

Authors:  David Blumenthal; William Hsiao
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

2.  Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis.

Authors:  Eishi Miyazaki; Masaru Ando; Tomoko Muramatsu; Tetsujiro Fukami; Osamu Matsuno; Shin-Ichi Nureki; Takuya Ueno; Tomiyasu Tsuda; Toshihide Kumamoto
Journal:  Clin Rheumatol       Date:  2005-12-20       Impact factor: 2.980

3.  Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis.

Authors:  Yoshioki Yamasaki; Hidehiro Yamada; Toshiko Nozaki; Jun Akaogi; Cody Nichols; Robert Lyons; Anthony Chin Loy; Edward K L Chan; Westley H Reeves; Minoru Satoh
Journal:  Arthritis Rheum       Date:  2006-06

4.  Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study.

Authors:  Y J Chen; C Y Wu; J L Shen
Journal:  Br J Dermatol       Date:  2001-04       Impact factor: 9.302

5.  Amyopathic dermatomyositis: a review by the Italian Group of Immunodermatology.

Authors:  Marzia Caproni; Carla Cardinali; Aurora Parodi; Barbara Giomi; Manuela Papini; Mario Vaccaro; Angelo Marzano; Clara De Simone; Marcello Fazio; Alfredo Rebora; Paolo Fabbri
Journal:  Arch Dermatol       Date:  2002-01

6.  Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine.

Authors:  Y Nawata; K Kurasawa; K Takabayashi; S Miike; N Watanabe; M Hiraguri; Y Kita; M Kawai; Y Saito; I Iwamoto
Journal:  J Rheumatol       Date:  1999-07       Impact factor: 4.666

7.  Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis.

Authors:  E H Kang; E B Lee; K C Shin; C H Im; D H Chung; S K Han; Y W Song
Journal:  Rheumatology (Oxford)       Date:  2005-06-21       Impact factor: 7.580

8.  Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.

Authors:  Jeffrey J Swigris; Amy L Olson; Aryeh Fischer; David A Lynch; Gregory P Cosgrove; Stephen K Frankel; Richard T Meehan; Kevin K Brown
Journal:  Chest       Date:  2006-07       Impact factor: 9.410

9.  Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases.

Authors:  N Basset-Seguin; J C Roujeau; R Gherardi; J C Guillaume; J Revuz; R Touraine
Journal:  Arch Dermatol       Date:  1990-05

Review 10.  A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.

Authors:  Pedram Gerami; Jennifer M Schope; Lauren McDonald; Hobart W Walling; Richard D Sontheimer
Journal:  J Am Acad Dermatol       Date:  2006-01-23       Impact factor: 11.527

View more
  58 in total

1.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

2.  Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations.

Authors:  Pamela A Morganroth; Mary Elizabeth Kreider; Joyce Okawa; Lynne Taylor; Victoria P Werth
Journal:  Arch Dermatol       Date:  2010-07

3.  Rapid progressive interstitial lung disease as initial manifestation of primary Sjögren's syndrome: a case report.

Authors:  Yihua Lin; Qun Yi; Deyun Cheng
Journal:  Int J Clin Exp Med       Date:  2014-12-15

4.  Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.

Authors:  Julio A Huapaya; Leann Silhan; Iago Pinal-Fernandez; Maria Casal-Dominguez; Cheilonda Johnson; Jemima Albayda; Julie J Paik; Abanti Sanyal; Andrew L Mammen; Lisa Christopher-Stine; Sonye K Danoff
Journal:  Chest       Date:  2019-06-22       Impact factor: 9.410

Review 5.  Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review.

Authors:  Dan Chen; Xiao-bing Wang; Yan Zhou; Xiao-chun Zhu
Journal:  Rheumatol Int       Date:  2013-05-29       Impact factor: 2.631

Review 6.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

Review 7.  Amyopathic dermatomyositis: definitions, diagnosis, and management.

Authors:  Elizabeth E Bailey; David F Fiorentino
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

Review 8.  Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.

Authors:  Kun Huang; Ophir Vinik; Kam Shojania; James Yeung; Rachel Shupak; Michael Nimmo; J Antonio Avina-Zubieta
Journal:  Rheumatol Int       Date:  2019-08-02       Impact factor: 2.631

9.  Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Masashi Akiyama
Journal:  Clin Rheumatol       Date:  2012-12-19       Impact factor: 2.980

10.  Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis.

Authors:  Hua Cao; Tanvi N Parikh; Jie Zheng
Journal:  Clin Rheumatol       Date:  2009-03-18       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.